Opendata, web and dolomites

LIsTEN SIGNED

β-Lactams as flaviviral NS3 protease inhibitors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LIsTEN project word cloud

Explore the words cloud of the LIsTEN project. It provides you a very rough idea of what is the project "LIsTEN" about.

improvement    catalytic    residue    adriatic    permeability    treatment    nile    billion    derivatives    strategy    consequence    ns3    disease    denv    host    previously    unnatural    parts    inhibitor    membrane    diseases    selectivity    coast    moiety    binding    inhibitors    replication    warhead    warming    sub    warheads    possibility    stability    tropical    beta    active    amino    living    reduce    group    asia    flaviviral    enzyme    america    biochemical    moderate    peptide    coupled    protease    potency    purpose    serine    site    mediterranean    acids    zikv    wnv    consist    accordingly    spread    infections    act    people    zika    affinity    synthesized    climate    threat    metabolic    outbreak    emerged    ameliorate    inhibitory    exist    off    assays    dengue    compounds    near    electrophilic    global    medical    regions    united    bond    agents    virus    moment    covalent    cell    incorporation    natural    lactams    lactam    culture    potent    valuable    west    significantly   

Project "LIsTEN" data sheet

The following table provides information about the project.

Coordinator
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG 

Organization address
address: SEMINARSTRASSE 2
city: HEIDELBERG
postcode: 69117
website: www.uni-heidelberg.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website https://www.ipmb.uni-heidelberg.de/chemie/klein/drazic.html
 Total cost 171˙460 €
 EC max contribution 171˙460 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-05-02   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG DE (HEIDELBERG) coordinator 171˙460.00

Map

 Project objective

Flaviviral infections already represent a threat to 2.5 billion people living in tropical and sub-tropical regions. As a consequence of climate change and global warming in the near future these infections are expected to spread to areas with moderate climate and the possibility of disease outbreak will exist in Europe, especially around the Mediterranean and Adriatic coast, as well as in the United States of America and large parts of Asia. At the moment no medical treatment against flaviviral diseases is available. Recently, peptide-based compounds which act as flaviviral NS3 protease inhibitors, emerged as potent agents against dengue virus (DENV), Zika virus (ZIKV) and West Nile virus (WNV). These compounds consist of two to four natural or unnatural amino acids and act by binding to the active site of the protease. Accordingly, the incorporation of an electrophilic warhead, a moiety which would facilitate the covalent binding of the inhibitor to the catalytic serine residue, into the peptide inhibitor represents a valuable strategy for the improvement of potency of such inhibitors. The goal of the proposed project is to investigate the potential of β-lactams as electrophilic warheads in DENV, ZIKV and WNV protease inhibitors. For that purpose, new β-lactam derivatives will be synthesized, coupled to peptide inhibitors previously developed by the host group and their affinity to the target will be evaluated by biochemical assays. The most potent compounds will be characterized in more detail and their activity against dengue virus replication in cell culture, off-target binding, membrane permeability and metabolic stability will be studied. We expect the formation of a covalent bond between inhibitor and active site of the enzyme to significantly improve inhibitory activity by increasing binding affinity, as well as to ameliorate selectivity and reduce off-target binding.

 Publications

year authors and title journal last update
List of publications.
2019 Tonko Dražić, Sara Kopf, James Corridan, Mila M. Leuthold, Branimir Bertoša, Christian D. Klein
Peptide-β-lactam Inhibitors of Dengue and West Nile Virus NS2B-NS3 Protease Display Two Distinct Binding Modes
published pages: 140-156, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b00759
Journal of Medicinal Chemistry 63/1 2020-02-12

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LISTEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LISTEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MY MITOCOMPLEX (2021)

Functional relevance of mitochondrial supercomplex assembly in myeloid cells

Read More  

POLINGO (2018)

The Politics of Legitimacy: Non-partisan global governance and networked INGO power in the global governance of post-war states

Read More  

LUNG-BIM (2019)

Induction of B cell immunity in the lung mucosa

Read More